A provision of the 1995 Dutch patent law has now come into force that gives pharmacists greater scope to compound lower-cost versions of patented medicines. The move could harm access to orphan medicines, lead to more parallel imports and undermine patient safety, claims the Dutch R&D-based pharmaceutical industry lobby group, Association Innovative Medicines.
The provision is part of Article 53 of the 1995 Patent Act, which sets out exclusive rights for patent right holders. It came into force on Feb 1 and now...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?